Name: Genetic Signatures (GSS) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

GSS

Pharmaceuticals, Biotechnology & Life Sciences

Genetic Signatures

Short interest: 0.00%; 0.00 pp 30d; as of 11 June 2026
Reported shorts: 7K
Shares on issue: 227.139M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Genetic Signatures

Genetic Signatures is a molecular diagnostics company focused on transforming diagnostics through streamlined sample processing and highly multiplexed real-time PCR screening assays. Their EasyScreen™ Detection Kits aim to simplify and improve the identification of infectious diseases. The company is based in Australia and has a global presence.

Company profile →

Genetic Signatures (ASX:GSS) has 0.00% of its shares on issue reported as short positions as of 11 June 2026, or about 7,000 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.37% in June 2024. GSS is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads GSS today

Zanger BreakoutWatchScore 10rank 1648 of 1942
CAN SLIMNot a candidate
Minervini Trend TemplateWatchScore 15rank 1142 of 1716
Crowded-Short BreakoutWatchScore 15rank 624 of 1500
Quality compoundersWatchScore 15rank 977 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

GSS fundamentals

In the year to 30 Jun 2026, Genetic Signatures (ASX:GSS) recorded revenue of A$14.5M and a net loss after tax of A$14.0M. A year earlier it recorded revenue of A$15.9M and a net loss after tax of A$20.1M. Year-on-year growth: revenue −9.1% (FY). Net margin −96.9%, return on equity −32.6% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →